Who Paid My Doc
Yana Najjar
Washington, DC Medical Doctor
NPI 1003112434 CMS profile 1381760
2111 Wisconsin Ave Nw, Apt 306, Washington, DC 20007
General payments
$133,415
Research payments
$6,455
Ownership & investment interest
$0
Research they led as principal investigator
$9,493,573
Through program year 2025, Yana Najjar of Washington, DC is reported in the CMS Open Payments database as having received $133,415 across 163 general payments and $6,455 in research payments paid to them. Separately, studies naming them as principal investigator received $9,493,573 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $43,985 | 65 | |
| 2024 | General | $42,308 | 40 | |
| 2024 | Research | $2,409 | 2 | |
| 2023 | General | $31,875 | 39 | |
| 2023 | Research | $4,045 | 1 | |
| 2022 | General | $15,007 | 16 | |
| 2020 | General | $53 | 1 | |
| 2019 | General | $186 | 2 |
Beside peers
- Yana Najjar
- District of Columbia median
- Middle half of District of Columbia
- National median
In program year 2025, general payments to Yana Najjar were reported at $43,985. Among 3,939 District of Columbia profiles paid that year, the median was $152 and the middle half received between $48 and $589.
Show as a table
| Year | Yana Najjar | District of Columbia median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $186 | $171 | $49–$733 | $163 |
| 2020 | $53 | $122 | $37–$508 | $114 |
| 2021 | $0 | $123 | $34–$501 | $132 |
| 2022 | $15,007 | $147 | $40–$541 | $149 |
| 2023 | $31,875 | $152 | $46–$653 | $160 |
| 2024 | $42,308 | $153 | $46–$657 | $164 |
| 2025 | $43,985 | $152 | $48–$589 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$41,229
Medicare patients
156
Services billed
425
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 48% | |
| Cancer | 37% | |
| Ischemic heart disease | 35% | |
| Diabetes | 27% | |
| Depression | 25% | |
| Chronic kidney disease | 23% | |
| Atrial fibrillation | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| KIMMTRAK |
|
$11,489 | — | — |
| BRAFTOVI |
|
$4,852 | — | — |
| MEKTOVI |
|
$4,216 | — | — |
| LORBRENA |
|
$150 | — | — |
| Hepzato Kit |
|
$125 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
166 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.